Neurogene Inc. (NGNE) Free cash flow 2016–2025
Neurogene Inc. (NGNE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$78.4MFY2025 · since FY2016: -$30.9M → -$78.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$78.4M | -9.7% |
| FY2024 | -$71.4M | -38.0% |
| FY2023 | -$51.7M | +6.0% |
| FY2022 | -$55.1M | -8.3% |
| FY2021 | -$50.8M | -89.7% |
| FY2020 | -$26.8M | -64.7% |
| FY2019 | -$16.3M | +48.5% |
| FY2018 | -$31.6M | +30.0% |
| FY2017 | -$45.2M | -46.1% |
| FY2016 | -$30.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NGNE financial trends
NGNE RevenueNGNE Net incomeNGNE Net marginNGNE Gross profitNGNE Gross marginNGNE Operating incomeNGNE Operating marginNGNE Operating cash flowNGNE Capital expendituresNGNE Return on equityNGNE Stock buybacksNGNE Dividends paidNGNE Total assetsNGNE Total liabilitiesNGNE Shareholders’ equityNGNE overview →